Invention Grant
- Patent Title: Universal cancer peptides derived from telomerase
-
Application No.: US14385534Application Date: 2013-03-07
-
Publication No.: US09669080B2Publication Date: 2017-06-06
- Inventor: Pierre Langlade Demoyen , Olivier Adotevi , Magalie Dosset
- Applicant: INVECTYS , Universite De Franche-Comte , Centre Hospitalier Regional Universitaire de Besancon
- Applicant Address: FR Paris FR Besancon FR Besancon
- Assignee: INVECTYS,Universite De Franche-Comte,Centre Hospitalier Regional Universitaire De Besancon
- Current Assignee: INVECTYS,Universite De Franche-Comte,Centre Hospitalier Regional Universitaire De Besancon
- Current Assignee Address: FR Paris FR Besancon FR Besancon
- Agency: Troutman Sanders LLP
- Priority: EP12305319 20120316
- International Application: PCT/EP2013/054592 WO 20130307
- International Announcement: WO2013/135553 WO 20130919
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C12N9/12 ; G01N33/50 ; G01N33/574
Abstract:
The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.
Public/Granted literature
- US20150283219A1 UNIVERSAL CANCER PEPTIDES DERIVED FROM TELOMERASE Public/Granted day:2015-10-08
Information query
